Vascular Endothelial Growth Factor, Soluble Fms-Like Tyrosine Kinase 1, and the Severity of Coronary Artery Disease

Kim, Soo‐Young; Lee, Sang-Hak; Park, Sungha; Kang, Seok Min; Chung, Namsik; Shim, Won-Heum; Cho, Seung-Yun; Jee, Sun Ha; Manabe, Ichiro; Jang, Yangsoo

doi:10.1177/0003319710370963

Cited by 17 publications

(15 citation statements)

References 33 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF changes in serum or plasma of patients with CAD relative to individuals without the disease varied from increased levels [15, 17] to decreased levels [16] or no changes [13, 22]. High VEGF levels were associated with patients who died of CAD [23] and with worst prognostic of ACS patients [14].…”

Section: Discussionmentioning

confidence: 99%

“…The observation of VEGF release from platelets during clotting [11] together with the detection of increased VEGF mRNA expression in specimens of myocardium with evolving infarction but not in normal tissue [12] called the attention for the possible association of the levels of this protein with CAD phenotypes. However, the reported increases of VEGF expression in the myocardium following acute events were not unequivocally detected in the serum of patients; neither have the changes of VEGF levels in different clinical presentations reached a consensus [13–16]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

et al. 2014

View full text Add to dashboard Cite

We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0–264 pg/mL versus 419, 212–758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167–498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173–497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

et al. 2014

View full text Add to dashboard Cite

show abstract

“…38 There are studies in hypertensive individuals indicating a relationship between sVEGFR1 and the coronary artery disease incidence and the severity of the disease. 39 If we assess these studies, we see that sVEGFR-1, apart from preeclampsia, plays an important role in the course of cardiovascular disease. One important finding in our study is that sVEGFR-1 levels in women with a history of preeclampsia were still higher on average 56 months after the termination of preeclamptic pregnancy.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women

Tuzcu¹,

Aşıcıoğlu²,

Sünbül³

et al. 2015

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

“…37 VEGF-A levels are increased in both acute and chronic myocardial ischemia and predict cardiac risk, 38 -40 whereas there are reports of both increased and decreased VEGFR-1 levels following myocardial infarction. 38,41 The reduced VEGFR-1 levels and VEGFR-1/VEGF-A ratio and nonsignificant 74% increase in VEGF-A levels in women, compared with men, in our study may therefore reflect their possible predisposition to ischemia attributable to their arteriolar hypertrophy and their greater diffusion radius relative to BSA and cardiomyocyte width.…”

Section: Discussionmentioning

confidence: 68%

Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease

et al. 2011

View full text Add to dashboard Cite

Abstract-Women younger than 75 years with stable angina or acute coronary syndrome have higher cardiac mortality than similarly aged men, despite less obstructive coronary artery disease. To determine whether the myocardial structure and coronary microvasculature of women differs from that of men, we performed histological analysis of biopsies from nonischemic left ventricular myocardium from 46 men and 11 women undergoing coronary artery bypass graft surgery who did not have previous cardiac surgery, myocardial infarction, heart failure, atrial fibrillation, or furosemide therapy. The 2 patient groups had similar clinical characteristics, apart from a lower body surface area (BSA) in women (Pϭ0.0015). Women had less interstitial fibrosis than men (Pϭ0.019) but similar perivascular fibrosis. Arteriolar wall area/circumference ratio, a measure of arteriolar wall thickness, was 47% greater in women than men (Pϭ0.012).Cardiomyocyte width and diffusion radius were positively correlated, and capillary length density was negatively correlated with BSA (PϽ0.05). Whereas cardiomyocyte width, capillary length density, diffusion radius, and cardiomyocyte width/BSA ratio were similar for men and women, women had a greater diffusion radius/BSA ratio (Pϭ0.0038) and a greater diffusion radius/cardiomyocyte width ratio (Pϭ0.027). Women also had lower vascular endothelial growth factor (VEGF) receptor-1 levels (Pϭ0.048) and VEGF receptor-1/VEGF-A ratio (Pϭ0.024) in plasma. We conclude that women with extensive coronary artery disease have greater arteriolar wall thickness and diffusion radius relative to BSA and to cardiomyocyte width than men, which may predispose to myocardial ischemia. Additional studies of larger numbers of women with less extensive coronary artery disease are required to confirm these findings. Key Words: gender Ⅲ ischemic heart disease Ⅲ myocardial fibrosis Ⅲ coronary microvasculature I schemic heart disease of women is different from that of men. 1,2 Women with stable angina referred for angiographic evaluation are less likely to have significant coronary artery disease, 3 yet women younger than 75 years with stable angina have a higher coronary standardized mortality ratio than men. 4 Moreover, when women present with an acute coronary syndrome, they are less likely to have an STsegment elevation myocardial infarction and more likely to have unstable angina, 5 and although they are less likely to have significant coronary artery disease, 3,5 women less than 75 years of age with myocardial infarction have a higher risk of coronary death than men. 3,6 -8 Evidence for a greater role for coronary microvascular dysfunction in ischemic heart disease of women is the report that retinal arterial narrowing, a marker of lower hyperemic myocardial blood flow and perfusion reserve, 9 predicted coronary events in women, but not in men. 10 To investigate the possibility that the different characteristics of ischemic heart disease in men and women reflect differences in myocardial structure and coronary microvascula...

show abstract

Vascular Endothelial Growth Factor, Soluble Fms-Like Tyrosine Kinase 1, and the Severity of Coronary Artery Disease

Abstract: Plasma sFlt-1 levels are positively associated with the presence of CAD and are associated with angiographical severity of CAD.

Cited by 17 publications

References 33 publications

Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women

Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease

Contact Info

Product

Resources

About